$2.74 Billion is the total value of BVF INC/IL's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $465,259,965 | +103.7% | 21,751,284 | 0.0% | 17.01% | +76.4% | ||
RPTX | REPARE THERAPEUTICS INC | $81,593,162 | -33.1% | 8,291,988 | 0.0% | 2.98% | -42.1% | |
GHRS | GH RESEARCH PLCordinary shares | $74,108,512 | -17.4% | 9,275,158 | 0.0% | 2.71% | -28.4% | |
FDMT | 4D MOLECULAR THERAPEUTICS IN | $68,887,429 | -22.6% | 4,007,413 | 0.0% | 2.52% | -33.0% | |
MRUS | MERUS N V | $54,802,928 | +18.9% | 2,978,420 | 0.0% | 2.00% | +3.0% | |
ZYMEWORKS INC | $53,064,800 | +15.0% | 5,870,000 | 0.0% | 1.94% | -0.4% | ||
CRNX | CRINETICS PHARMACEUTICALS IN | $43,950,005 | -12.2% | 2,736,613 | 0.0% | 1.61% | -24.0% | |
IMVT | IMMUNOVANT INC | $39,721,110 | -12.6% | 2,561,000 | 0.0% | 1.45% | -24.3% | |
LXRX | LEXICON PHARMACEUTICALS INC | $39,242,505 | +27.2% | 16,149,179 | 0.0% | 1.44% | +10.2% | |
CTIC | CTI BIOPHARMA CORP | $37,014,688 | -30.1% | 8,813,021 | 0.0% | 1.35% | -39.5% | |
RAIN | RAIN ONCOLOGY INC | $30,823,611 | +9.2% | 3,526,729 | 0.0% | 1.13% | -5.4% | |
OLMA | OLEMA PHARMACEUTICALS INC | $26,411,915 | +41.6% | 7,611,503 | 0.0% | 0.96% | +22.6% | |
EPIX | ESSA PHARMA INC | $25,983,428 | +17.9% | 8,748,629 | 0.0% | 0.95% | +2.2% | |
ITOS | ITEOS THERAPEUTICS INC | $24,645,464 | -30.3% | 1,810,835 | 0.0% | 0.90% | -39.7% | |
NEWAMSTERDAM PHARMA COMPANYordinary shares | $20,454,981 | +27.8% | 1,521,948 | 0.0% | 0.75% | +10.7% | ||
THIRD HARMONIC BIO INC | $17,987,644 | -4.2% | 4,365,933 | 0.0% | 0.66% | -16.9% | ||
CALT | CALLIDITAS THERAPEUTICS ABsponsered ads | $17,962,500 | +36.6% | 750,000 | 0.0% | 0.66% | +18.4% | |
VIGIL NEUROSCIENCE INC | $17,755,467 | -21.7% | 1,813,633 | 0.0% | 0.65% | -32.2% | ||
OVID | OVID THERAPEUTICS INC | $17,675,712 | +38.7% | 6,851,051 | 0.0% | 0.65% | +20.1% | |
ACIU | AC IMMUNE SA | $17,382,407 | +14.7% | 7,428,379 | 0.0% | 0.64% | -0.8% | |
STRO | SUTRO BIOPHARMA INC | $15,467,511 | -42.8% | 3,347,946 | 0.0% | 0.56% | -50.5% | |
AN2 THERAPEUTICS INC | $15,436,315 | +3.6% | 1,563,963 | 0.0% | 0.56% | -10.3% | ||
GLYC | GLYCOMIMETICS INC | $12,025,770 | -58.4% | 9,544,262 | 0.0% | 0.44% | -63.9% | |
CTMX | CYTOMX THERAPEUTICS INC | $9,959,660 | -5.6% | 6,595,801 | 0.0% | 0.36% | -18.2% | |
ARAV | ARAVIVE INC | $9,568,428 | +51.5% | 4,784,214 | 0.0% | 0.35% | +31.1% | |
VERV | VERVE THERAPEUTICS INC | $9,373,000 | -25.5% | 650,000 | 0.0% | 0.34% | -35.4% | |
SLN | SILENCE THERAPEUTICS PLCads | $9,352,179 | -59.3% | 1,508,416 | 0.0% | 0.34% | -64.8% | |
CDTX | CIDARA THERAPEUTICS INC | $8,713,631 | +67.9% | 6,861,127 | 0.0% | 0.32% | +45.7% | |
NLSP | NLS PHARMACEUTICS LTD | $8,678,160 | +17.1% | 5,747,126 | 0.0% | 0.32% | +1.3% | |
VSTM | VERASTEM INC | $7,898,207 | +3.2% | 19,022,656 | 0.0% | 0.29% | -10.5% | |
VIRX | VIRACTA THERAPEUTICS INC | $5,747,313 | +8.9% | 3,614,662 | 0.0% | 0.21% | -5.8% | |
ELDN | ELEDON PHARMACEUTICALS INC | $5,491,036 | +1.7% | 2,326,710 | 0.0% | 0.20% | -11.8% | |
PIRS | PIERIS PHARMACEUTICALS INC | $4,958,392 | -6.2% | 5,080,320 | 0.0% | 0.18% | -18.8% | |
ELEV | ELEVATION ONCOLOGY INC | $4,393,180 | +100.5% | 2,312,200 | 0.0% | 0.16% | +75.0% | |
HILLEVAX INC | $4,109,011 | -1.2% | 248,579 | 0.0% | 0.15% | -14.8% | ||
MOLN | MOLECULAR PARTNERS AGads | $2,659,326 | -7.4% | 443,221 | 0.0% | 0.10% | -19.8% | |
IVA | INVENTIVA SAads | $2,497,186 | -17.8% | 686,040 | 0.0% | 0.09% | -28.9% | |
MTEM | MOLECULAR TEMPLATES INC | $1,898,195 | +15.8% | 4,996,565 | 0.0% | 0.07% | 0.0% | |
IMUX | IMMUNIC INC | $1,712,643 | +6.4% | 1,149,425 | 0.0% | 0.06% | -7.4% | |
CRVS | CORVUS PHARMACEUTICALS INC | $1,247,562 | +7.1% | 1,370,947 | 0.0% | 0.05% | -6.1% | |
INFI | INFINITY PHARMACEUTICALS INC | $1,016,583 | -71.2% | 6,353,645 | 0.0% | 0.04% | -75.2% | |
ANGN | ANGION BIOMEDICA CORP | $621,352 | -28.5% | 1,071,297 | 0.0% | 0.02% | -37.8% | |
RZLT | REZOLUTE INC | $366,365 | -7.2% | 190,815 | 0.0% | 0.01% | -23.5% | |
BIONOMICS LIMITEDads | $210,525 | -43.6% | 80,971 | 0.0% | 0.01% | -50.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
ARQULE INC | 27 | Q4 2019 | 4.8% |
CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-01-29 |
3 | 2024-01-26 |
4 | 2024-01-09 |
4 | 2023-12-20 |
4 | 2023-11-17 |
13F-HR | 2023-11-14 |
3 | 2023-11-13 |
3 | 2023-11-06 |
4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.